XNW4107 is a broad spectrum, best-in-class BLI inhibitor of the diazabicyclooctane (DBO) class for all three classes of A/C/D SBL. XNW4107 has successfully completed Phase III registration study in HABP/VABP and is currently at NDA stage.

XNW5004 is a best-in-class selective EZH2 inhibitor. In September 2024, XNW5004 was granted BTD (Breakthrough Therapy Designation) by CDE for relapsed or refractory peripheral T-cell lymphoma (PTCL). Pivotal studies in PTCL are ongoing.

XNW27011¹ and XNW28012 are topoi-based ADCs, both programs are currently in Phase III studies, with superior efficacy and safety observed across a broad range of solid tumors.

XNW27011¹ and XNW28012 are topoi-based ADCs, both programs are currently in Phase III studies, with superior efficacy and safety observed across a broad range of solid tumors.

XNW1011² is a next-generation BTK inhibitor. It can treat a variety of diseases, including B-cell-related hematological malignancies, primary membranous nephropathy, and IgA nephropathy, by targeting the B-cell receptor (BCR) signaling pathway.

XNW29016 is a first-in-class PARG inhibitor entering Phase I clinical study. In preclinical studies, XNW29 has demonstrated robust efficacy, excellent PK properties and good safety profile.

XNW34017 is a novel heterobifunctional degrader discovered through our TPD platform. The lead asset is currently in IND-enabling studies, with high oral bioavailability, outstanding in vivo efficacy, and manageable AE profile observed in preclinical studies